The latest price target for Inozyme Pharma (NASDAQ:INZY) was reported by Piper Sandler on January 13, 2025. The analyst firm set a price target for $30.00 expecting INZY to rise to within 12 months (a possible 2012.68% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Inozyme Pharma (NASDAQ:INZY) was provided by Piper Sandler, and Inozyme Pharma maintained their overweight rating.

The last upgrade for Inozyme Pharma Inc happened on March 23, 2023 when Jefferies raised their price target to $6. Jefferies previously had a hold for Inozyme Pharma Inc.

There is no last downgrade for Inozyme Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a maintained with a price target of $43.00 to $30.00. The current price Inozyme Pharma (INZY) is trading at is $1.42, which is out of the analyst’s predicted range.